a chalkboard guide to the research
BPC-157 is a research peptide with a wide preclinical record and a very narrow human one — here is what the studies measured.
A plain-English reading of the published literature on BPC-157: the angiogenesis mechanism, the pharmacokinetics, the tissue-repair findings, and an honest map of where the evidence stops.
Start at the board: what BPC-157 is, in one lesson
BPC-157 is a synthetic 15-amino-acid peptide that has accelerated tendon, gut, muscle, and vascular repair across decades of animal studies. The name stands for Body Protection Compound 157, and it is derived from a partial sequence of a protein isolated from human gastric juice [5]. Almost everything measured about it has been measured in rodents — a point this whole site keeps in view.
The single most consistent finding in the literature is angiogenesis: in injured tissue, BPC-157 promotes the formation of new blood vessels [3]. The repair effects across skin, muscle, tendon, ligament, and bone are organized around that cytoprotective, vessel-building mechanism [5]. The peptide is often called a stable gastric pentadecapeptide because it is reported to remain stable in gastric juice [2]. The breadth of that tendon and musculoskeletal repair research is real and reproducible across models.
What the studies do not establish is just as important. Human evidence is limited to three small pilot studies, large controlled trials are lacking, and BPC-157 is not an approved drug anywhere [11]. A 2025 narrative review reads the same record and concludes it should be treated as investigational [11]. The BPC-157 safety signals so far are reassuring within a tiny dataset, which is not the same as proven safety. That tension — broad rodent evidence, thin human evidence — is the lesson worth learning first. The sections below walk through it, the FDA 503A compounding category is covered on its own page, and every quantitative claim is chalked to a citation you can check on the full reference list.
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a stable gastric pentadecapeptide studied as a research peptide for cytoprotection and tissue repair; it is not an approved drug and is studied chiefly in animal models [11]. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fifteen-amino-acid chain with a molecular weight near 1419.53 Da [5]. It is a synthetic fragment, not a peptide that circulates naturally in the body.
BPC-157, the Stable Gastric Pentadecapeptide
The BPC-157 peptide is a chemically synthesized 15-amino-acid sequence derived from a partial sequence of the Body Protection Compound found in human gastric juice [5]. "Pentadecapeptide" simply means fifteen amino acids. Researchers call it a stable gastric pentadecapeptide because, unlike many peptides, it is reported to survive the acidic environment of gastric juice [2] — the property behind interest in oral routes.
It is usually supplied as the acetate salt and carries the identifiers CAS 137525-51-0 and PubChem CID 108101. As a peptide it sits in the cytoprotective/regenerative research class rather than among hormones or approved medicines. The 2022 pharmacokinetic study confirmed it behaves predictably in the body — linear pharmacokinetics, a short elimination half-life, and rapid breakdown into small fragments that re-enter normal amino-acid metabolism [2]. The identity is settled; the open questions are about what it does in people, covered across the BPC-157 research benefits and research pages.
What does BPC-157 do in the body?
In animal models, BPC-157 is described as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis. The pathway runs through up-regulation and internalization of the VEGFR2 receptor, with downstream Akt-eNOS (nitric-oxide) signaling [3]. New vessels mean better-perfused tissue, which is the through-line connecting its findings in tendon, gut, and ischemic muscle [3].
Is BPC-157 a growth hormone?
No. BPC-157 is a synthetic 15-amino-acid pentadecapeptide, not a growth hormone [5]. One tendon-fibroblast line of research reports that it up-regulates the growth-hormone receptor in those cells, which is a distinct mechanism from being a hormone itself. The distinction matters: BPC-157 is studied as a tissue-repair peptide, not a hormone-replacement compound.
How is BPC-157 made?
BPC-157 is a synthetic peptide: a chemically manufactured 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of the Body Protection Compound found in human gastric juice [5]. It is often supplied as the acetate salt. It is assembled in a laboratory, not extracted from tissue, and is sold by research suppliers for laboratory use rather than as a finished medicine.